A) Additional Statistical Information on Methods
The statistical methods include: initial exploratory data analyses using clustering of the UKPSSR discovery cohort; development of the Newcastle Sjogren's syndrome Stratification tool (NSST) using multinomial regression based on the initial clustering approach (which is the stratification model that we subsequently validate using independent cohorts); linear modelling of subgroup differences across discovery and validation cohorts; and re-analyses of two phase III clinical trials, testing for differences between treatments and placebo controls for the different subgroups. We used clustering analysis on patient-reported symptoms to identify patients with similar symptomology, tested for heterogeneity in biological and clinical variables between those clusters, developed a classification tool permitting patients from independent cohorts to be assigned to symptom-based subgroups, tested whether those same biological and clinical effects were replicated in those independent cohorts, before going on to use the classification tool to stratify patients from two historical clinical trials testing for differences in therapeutic response (see Supplementary Figure S1 ).
1. We used two validated instruments to collect Patient Reported Outcome data [1] [2] [3] [4] : a) Pain, fatigue and dryness were measured using EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) which consists of 3 domains: Pain, Fatigue and Dryness. Each domain uses a numeric scale of 0-10 indicating "No symptom" to "Worst imaginable symptom". The reliability of ESSPRI is supported by the study by Seror R et al [2] . In this study, 395 patients (from 15 countries) were asked to complete the ESSPRI questionnaire two days apart. The intra-rater correlation coefficient was excellent (0.94 (CI: 0.89, 0.97)). A difference of one unit on the ESSPRI is considered of clinical significance and it is accepted to be the response criteria for clinical studies in pSS. b) Anxiety and depressive symptoms were measured using Hospital Anxiety and Depression scale (HADS). HADS was developed in 1983 as a screening instrument for use in hospital outpatient departments (the same setting of the three cohorts) and has been extensively used in many studies. In a systematic review performed in 2000, of 747 studies [2] , the mean Cronbach's alpha (a measure of internal consistency) for HADS-Anxiety and HADS-Depression scores were very good (0.83 and 0.82 (CI: 0.68-0.93 and 0.67-0.90 respectively)).
Therefore, these two instruments are appropriate tools for the evaluation of these five symptom domains.
2. All statistical tests and graphical rendering were performed using the R statistical package, SAS and SAS JMP Statistical Data Visualization software [5] [6] [7] . Except where stated we used a probability value of p<0.05 as the threshold for all statistical significance tests. Otherwise we used a FDR-adjusted Benjamini-Hoechberg probability value threshold of p<0.05.
3. In the exploratory data analysis during the discovery phase of this study, the initial clusters -based on symptom scores for patients in the UKPSSR -were identified using Ward's hierarchical clustering method. The decision to use hierarchical clustering was supported by our Analytical Team (comprising statisticians (DWL, BCL), bioinformaticians (AJS, JC), data scientists (JRT) as well as clinicians (WFN, JDI and the majority of the co-authors)). Hierarchical Clustering assumes a hierarchy of symptoms that is consistent with the clinical expectations of the relationships between the clusters. Furthermore, Ward's method performs well in the absence of multivariate outliers and with relatively low dimensional hierarchical data (in this case only 5 dimensions). Using the cubic clustering criterion, Ward's method supported up to five candidate clusters, while alternative metrics such as the pseudot 2 supported just two clusters.
Ultimately, four clusters were selected by the Analytical Team based upon heat maps of the severity scores of the five common pSS symptoms (ESSPRI-pain, ESSPRI-fatigue, ESSPRI-dryness, HADS-anxiety and HADS-depression). As shown in the dendrogram and heatmap of Figure 1A (and below), a 2cluster model would yield the LSB cluster, with the remaining patients (i.e. those from the HSB, DDF and PDF groups) being classified as a single cluster which consists of a subgroup with highly heterogeneous levels of symptoms. Given that the LSB subgroup is least likely to seek medical intervention, the 2-cluster stratification model has limited clinical utility. A 3-cluster model would identify the HSB cluster, as well as the LSB cluster, with the third cluster consisting of the DDF and PDF patients, a heterogeneous group of patients with low levels of symptoms of anxiety and depression but variable levels of symptoms of pain, fatigue or dryness. In contrast, the 4-cluster model identified an additional subgroup with severe symptoms of dryness but minimal symptoms of pain. We excluded a fifth candidate cluster -a subset of PDF patients with low levels of anxiety and depression and high levels of pain, fatigue and dryness -because of its small size. For similar reasons the Analytical Team decided against models with higher numbers of clusters. Therefore, the 4-cluster model was taken forward for validation against independent cohorts. Figure 1A (modified) illustrated the group membership for two to five cluster models. 4 . Given the uncertainties inherent in clustering analysis, and in particular the choice of number of clusters, we later repeated the clustering exercise using a variety of alternative clustering methods. In particular, interest centred on the choice of the number of candidate clusters. These methods included centroids, nearest neighbours, k-means, Gaussian mixtures and more modern methods including Markov consensus clustering. The optimal number of clusters was explored using Cubic Clustering Criteria, Pseudo-F and Pseudo-t 2 statistics, AIC, BIC and other metrics as appropriate for the method. These additional clustering approaches generally favoured fewer clusters: while all of the clustering methods identified a low symptom burden cluster, the breakdown of the remaining patients was more nuanced. The decision to take forward four stratification subgroups was taken in the knowledge that these could be collapsed in the event that they were not clinically useful. The fact that we were able to recapitulate the clinical and biological findings in independent cohorts based on the four-cluster model provides a level of confidence in this decision. That symptom-based subgroups were effective in identifying biologically and clinically important differences which were subsequently validated in two external, independent cohorts, indicates that our stratification approach is robust. 5. Rather than using the clustering formula directly, we chose to create a simple classification tool allowing us -and other researchers -to assign patients to subgroups based upon patient reported symptom scores. Having already used unsupervised clustering methods to identify clusters, we were then able to switch to supervised methods predicting cluster membership. We considered using the original clustering formula for classification, but took the view that clinicians in our field are probably more familiar with logistic and multinomial regression as classification tools. Since we had now identified candidate clusters, we were able to build a supervised multinomial regression model for this purpose [8] . This model predicted membership of the four clusters based on ESSPRI and HADS scores for a randomly selected, two-thirds training set of the UKPSSR cohort. The model predicted cluster membership based upon Pain, Fatigue, Dryness, Anxiety and Depression scores. We then tested this model using the remaining, one-third hold-out data set. We compared predicted cluster membership using the classification tool, to the actual observed cluster membership for each patient in the hold-out set. We estimated ROC AUC values for the four subgroups (see Supplementary Figure  S2 below). The model performed well in the hold-out validation set. Model estimates and standard errors are available in the Excel stratification workbook (see Supplementary Figures S2B and S4 below). This model was then used as a tool to classify patients into the four symptom-based subgroups for the independent validation observational cohorts and JOQUER and TRACTISS clinical trial cohorts. Note that this approach permitted stratification of patients from independent cohorts and historical clinical trials. Recapitulation of the biological and clinical findings between subgroups in independent cohorts and trials lends strong support to the notion that these represent biologically and clinically meaningful subgroups underpinned by pathobiological differences.
The NSST is available to academic/non-commercial researchers as an Excel macro algorithm to stratify pSS patients based on these five key symptoms into the LSB, DDF, HSB and PDF subgroups. The NSST can be accessed via the following weblink: https://github.com/SJOGRENS/Symptom-Based-Subgroups. Note that the users are required to obtain a password from the Analytic team and to confirm that the use of the algorithm is for non-commercial research projects.
6. Summary data -including either medians and quartiles, or means and standard deviations for continuous data, or percentages for counts data -are presented for clinical and laboratory variables. Kruskal-Wallis analysis of ranks -an omnibus test for overall group heterogeneity -permitted screening of clinical and laboratory variables for differences between subgroups. For discrete data, contingency table methods were used and chi-square or exact permutation tests computed testing for differences between subgroups. In particular, tests for differences in the prevalence of lymphoma are based on exact, permutation-based methods rather than large sample approximations. Please note that the Kruskal-Wallis analysis is an omnibus test of overall heterogeneity between subgroups. Note that, rather than attempting to control false discoveries through p-value adjustments, we instead took forward the full list of prospective candidates parameters (see below) to the next stage for validation in the independent cohorts.
Basic clinical and demographic parameters that were recorded include age, sex, body mass index (BMI), AECG duration, ESSDAI and ESSPRI. The 18 candidate clinical variables were: Haemoglobin, Total white cell count, Neutrophils, Lymphocytes, Platelet, ESR, CRP, Thyroid stimulation hormone, Complement component 3, Complement component 4, IgG, IgA, IgM, Ro/La positivity, Schirmer's, unstimulated salivary flow, lymphoma prevalence*, EQ-5D*. The 8 candidate serum protein variables were ĸ-FLC, λ-FLC, combined FLC, BAFF, β2m, CXCL13, IL-17*, TNF-α*.
[*denotes variables which were not available from the independent cohorts for validation]. We have also included the corresponding p-values after Benjamini-Hochberg FDR corrections in Supplementary  Tables S2.1 and S2.2. For the analysis of transcriptomics for which the multiplicity problem is more substantial, the candidate list needed to be reduced. Here we either performed Benjamini-Hochberg adjustments when testing individual modules or constructed canonical variables for discriminant analysis. Note that in the main text, we used unadjusted p-values when comparing individual annotated transcriptomic modules between subgroups.
7. For comparison of cohorts, linear models were constructed using rank-transformed variables including terms for Subgroup, Cohort and their interaction: Subgroup x Cohort. The Subgroup x Cohort interaction test was used as a 'consistency' test checking that the differences between Subgroups were consistent across the Cohorts. In addition, linear models were constructed to analyse logtransformed serum proteins, permitting the estimation of differences between subgroups, cohorts, and their interaction. Again, the interaction term was used to assess 'consistency' between subgroups across the cohorts.
8. We performed discriminant analysis on the Chaussabel module scores, plotting the location of each patient in canonical space (see supplementary Figure S3 ). Canonical variables are linear combinations of the individual module scores permitting discrimination of the phenotypes after adjustment for differences between cohorts. In addition, these Canonical variables are multivariate normally distributed and orthogonal to each other. Each phenotype has a multivariate centroid and measurable variability around that centroid. This permits statistical testing for differences between phenotypes in transcriptomic space and calculation of multivariate confidence intervals [9] . Canonical plots are presented -together with the 50% ellipsoids about the centroid of each sub-group -separately for the UKPSSR and ASSESS cohorts. The 50% density ellipsoids are calculated as the multivariate mean, or centroid, ± 0.6 multivariate standard deviations. 50% is the default in many systems as it captures the location of the bulk of the data without obscuring their relative separation. While the entropy R2 for the discriminant model is 69% and the ROC AUC for each of the subgroups is greater than 0.90, we avoided making exaggerated claims for this model and instead use the results to simply visualize the separation and relative locations of the four phenotypic subgroups in transcriptome space for the two cohorts.
9. In order to compare the performance of symptom-based stratification and stratification by disease activity, we stratified the UKPSSR and ASSESS data using the EULAR Sjögrens Syndrome Disease Activity Index (ESSDAI). This separates patients with Low, Moderate and High systemic disease activity (ESSDAI scores 0-4, 5-13, ≥14 respectively). We found that stratification by symptoms (i.e. using the NSST) out-performed stratification by disease activity. The NSST stratification identifies more clinical and biologically meaningful differences. In addition we compared the goodness of fit of the two stratification models by comparing the residual deviances after fitting the NSST-based and ESSDAIbased strata to the transcriptomics data. The residual deviance was consistently minimized for the NSST-based stratification model compared to the ESSDAI-based model. The NSST-based model gave a better model fit than the ESSDAI-based model on 70 of the 100 Chaussabel modules (binomial test, p = 0.00037). In addition, we repeated the analysis using a four-level ESSDAI categorization -inactive (0), low (1) (2) (3) (4) , moderate (5-13), high (14 or above). This means that the number of groups is equal and the degrees of freedom identical for model comparison. This slightly reduces the number of modules for which the NSST-based stratification shows the better fit -from 70 to 68 of the 100 modules (binomial test, p=0.0004).
10. For the JOQUER and TRACTISS trials, we analysed the primary outcome variable-change in ESSPRI scores from baseline to the end of the trial -including terms for Subgroup and Treatment and their interaction: Subgroup x Treatment. We then formed contrasts to compare Treatments within each Subgroup. For the TRACTISS trial there was no statistically significant effect on the change in ESSPRI scores from baseline to the end of the trial. However, there were significant differences for the secondary outcomes -unstimulated and stimulated salivary flow, USF and SSF respectively. USF and SSF were bounded by zero and positively skewed. Accordingly, analyses were performed on log transformed data: log10(USF+k) and log10(SSF+k) where k is a small constant (k=10 -2 ). There were statistically significant differences in both USF and SSF in the DDF subgroup. In the JOQUER trial there were clinically important differences in ESSPRI for both the HSB and LSB subgroups -though only the former was statistically significant.
B) Analytical Methods

Transcriptomics
Whole blood PAXgene RNA samples from the UK cohort were assayed by Illumina Human HT-12 v4 Expression BeadChip. Globin signal suppression was performed using the Affymetrix Globin Reduction protocol. The ASSESS data were derived from whole blood PAXgene RNA samples using a Clariom S Human transcriptome-wide gene expression profiling assay. Analysis of both arrays was performed using Bioconductor libraries in the R environment for statistical computing.
Serum Protein analysis
Serum κ-free light chain (FLC) and λ-FLC (Freelite®, The Binding Site Group Ltd), combined FLC (cFLC, Combylite TM ), and beta 2 microglobulin (β2M) on the SPAPLUS® turbidimeter (The Binding Site Group Ltd) were assayed following the manufacturer's recommendations. BAFF and CXCL13 were measured using a commercially available enzyme immunoassay (Human BAFF/BLyS/TNFSF13B and CXCL13/BLC/BCA-1 Quantikine ELISA Kits, R&D Systems, Abingdon UK) following the manufacturer's instructions. These data were derived from samples collected at the time of recruitment and are contemporaneous to the clinical data presented.
C) Supplementary figures
Supplementary Figure S1. Supplementary Figure S1 : Flow diagram showing stratification strategy and cohorts used for discovery, validation of biological findings in independent international cohorts, and evaluation of therapeutic utility. The UKPSSR cohort formed the Discovery Cohort (n=608) and the ASSESS (n=334) and Stavanger cohorts (n=62) were used as the external Validation Cohorts. Using patient reported symptom scores ① we identified four major clusters ②. Clusters showed marked differences in objectively measured clinical and laboratory data ③. We then created a stratification tool (NSST) permitting other cohorts to be stratified using this symptom-based stratification approach ④. We used the NSST to stratify patients in the ASSESS and Stavanger cohorts confirming the biological and clinical differences observed in the UKPSSR cohort ⑤. We observed also consistent differences in the transcriptomic profiles of our symptom-based subgroups across the UKPSSR (n=196) and the ASSESS cohorts (n=312) ⑥. The theragnostic potential of these findings is illustrated using the NSST ④ to stratify patients in two phase III clinical trials -JOQUER (n=107) and TRACTISS (n=114). We identified distinct subgroups responding respectively to hydroxychloroquine (HSB) and rituximab (DDF) treatments ⑦. The number of HSB patients in the JOQUER trial was 32 (hydroxychloroquine = 14 and placebo = 18). The number of DDF patients in the TRACTISS study was 26 (rituximab=13, placebo=13 Transcriptomics Data
Figure 1
Supplementary Figure S2A Training Testing Supplementary Figure S2A : Receiver Operating Characteristic Curves for the Newcastle Sjögren's Stratification Tool (NSST) for the Training and Testing datasets. To develop a stratification tool permitting symptom-based subgroup membership to be identified based upon the patient reported symptom scores we fitted a multinomial logistic regression model to a randomly chosen training subset of 421 pSS patients from the UK discovery cohort. The Receiver Operating Characteristic (ROC) curve for this model is presented along with the corresponding ROC curve for the holdout testing dataset of the remaining one-third (187) patients. The sensitivity and specificity of the NSST is excellent with an Area Under the Curve (AUC) for the ROC curves >0.95 for all four symptom-based subgroups, indicating that this stratification tool faithfully represents the initial clustering-based approach. To permit other researchers to use this classification tool we provide an Excel macro of this stratification tool permitting pSS patients to be assigned to the HSB, LSB, DDF and PDF subgroups based on the severity of their five key symptoms.
Supplementary Figure S2B
Parameter estimates and standard errors for the multinomial logistic regression model (i.e. the NSST algorithm). Supplementary Table S1 Supplementary Table S1: Key clinical, demographic and phenotypic data for the UKPSSR, ASSESS and Stavanger cohorts. Except where indicated, summary statistics are presented as percentages or median values with 25 th and 75th centile values in parentheses, and probability values are for the Kruskal-Wallis rank analysis. Age, sex, BMI, disease activity (ESSDAI) and symptom scores (ESSPRI) are shown for the three cohorts. All three cohorts were made up largely of females around sixty years of age, with an AECG diagnosis of between five and eleven years in duration, and with comparable disease activity scores and symptom scores. Supplementary Table S3 Supplementary 
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D) Supplementary Tables
0·0295 # 0·2644 0·0240 <0·0001 Lymphocytes (x10 9 /L) UKPSSR ASSESS Stavanger Combined 1·2 (1.0, 1·6) 1·3 (1.0, 1·8) 1·4 (0·7, 1·7) 1·3 (1.0, 1·6) 1·5 (1·2, 1·8) 1·5 (1·1, 1·7) 1·9 (1·6, 2·4) 1·5 (1·2, 1·7) 1·3 (1.0, 1·7) 1·2 (1.0, 1·6) 1·2 (0·9, 1·4) 1·2 (1.0, 1·7) 1·3 (1·0, 1·7) 1·5 (1·1, 1·8) 1·8 (1·3, 2.0) 1·4 (1·1, 1·8) 0·0009 # 0·0251 0·0303
